LOS ANGELES, USA | March 24, 2026
Turn Therapeutics, Inc., a clinical-stage dermatology-focused biotechnology company, has announced a strategic financing agreement of up to $25 million with Avenue Capital Group, marking a critical step in advancing its pipeline of innovative treatments for inflammatory skin diseases. The funding includes an initial $7 million tranche at closing, with an additional $18 million tied to clinical and corporate milestones, providing the company with significant financial flexibility to accelerate development of its lead programs.
Strategic Financing to Accelerate Clinical Development
This growth capital loan facility is expected to extend Turn Therapeutics’ operational runway through key milestones, including the anticipated Phase 2 clinical trial readout for moderate-to-severe atopic dermatitis expected mid-2026. The funding will also support preparations for registrational trials of GX-03, the company’s lead candidate, and is projected to extend financial runway through the end of 2027 if fully utilized. This financing comes at a pivotal time as the company transitions from early-stage clinical validation to late-stage development and potential commercialization pathways. The structured financing approach reflects strong investor confidence while minimizing immediate dilution for shareholders.
GX-03 Shows Promise Across Multiple Dermatology Indications
Turn Therapeutics’ lead asset, GX-03, is a first-in-class, non-systemic topical therapy designed to address moderate-to-severe atopic dermatitis (eczema) as well as onychomycosis (nail fungus). Early independent human data have shown encouraging efficacy signals, particularly in onychomycosis, where current treatment options remain limited and often ineffective. GX-03’s unique topical, non-systemic mechanism offers potential advantages in safety and patient compliance compared to systemic therapies. The company is advancing GX-03 across multiple indications simultaneously, aiming to deliver broad therapeutic impact in dermatology, a field with significant unmet medical needs and growing global demand.
Advertisement
Strengthening Position in Dermatology Innovation
The partnership with Avenue Capital Group, a global investment firm managing over $11 billion in assets, underscores the growing interest in dermatology-focused biotech innovation. The financing structure aligns capital deployment with clinical progress, ensuring disciplined growth while enabling rapid advancement of promising therapies. As the global dermatology therapeutics market expands, driven by rising prevalence of chronic inflammatory skin conditions, Turn Therapeutics is positioning itself as a key innovator with differentiated treatment approaches. The company’s focus on precision therapies and targeted delivery systems reflects broader industry trends toward safer, more effective, and patient-friendly treatments.
With this strategic funding, Turn Therapeutics is well-positioned to accelerate clinical milestones, advance its pipeline of novel dermatology therapies, and deliver transformative solutions for patients suffering from chronic skin diseases worldwide.
Source: Turn Therapeutics press release
